. Author manuscript; available in PMC: 2021 Mar 22.

Published in final edited form as: Biochem Pharmacol. 2018 Jul 17;155:316–325. doi: 10.1016/j.bcp.2018.07.018

Table 2.

The effect of tariquidar and Ko143 on the cytotoxicity of ricolinostat in cells overexpressing ABCB1 or ABCG2.

Cell line	Mean IC₅₀ ± SD [μM]^† and (FR^‡)
	Ricolinostat	Ricolinostat + tariquidar	Ricolinostat + Ko143
KB-3–1	4.28 ± 0.71 (1.0)	6.94 ± 1.83 (0.6)	N.D
KB-V-1	24.18 ± 2.05 (1.0)	3.90 ± 1.09^*** (6.2)	N.D
S1	3.06 ± 0.21 (1.0)	N.D	3.02 ± 0.30 (1.0)
S1-M1–80	69.01 ± 5.79 (1.0)	N.D	2.21 ± 0.18^*** (31.2)
pcDNA-HEK293	3.40 ± 0.50 (1.0)	2.05 ± 0.30^* (1.7)	2.19 ± 0.26^* (1.6)
MDR19-HEK293	22.35 ± 2.05 (1.0)	3.36 ± 0.44^*** (6.7)	N.D
R482-HEK293	40.25 ± 4.36 (1.0)	N.D	7.52 ± 1.01^*** (5.4)

Abbreviation: N.D, not determined. FR, fold reversal.

^†

IC₅₀ values are mean ± SD in the presence and absence of 1 μM tariquidar or 1 μM Ko143. The IC₅₀ values were calculated from dose-response curves obtained from three independent experiments.

^‡

FR values were obtained by dividing IC₅₀ values of cells treated with ricolinostat in the absence of tariquidar or Ko143 by IC₅₀ values of cells treated with ricolinostat in the presence of tariquidar or Ko143.

P < 0.05;

^**

P < 0.01;

^***

P < 0.001.